sellWeak
Novo Holdings A/S sold $802k of IOBT
owner at IO Biotech, Inc.. 658,809 shares at an average of $1.22, traded May 10, 2024, filed May 14, 2024.
Warning score
39Value
$802k
658,809 shares
Holdings after
4,429,449
-13% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +22Trade size$802k at market
- +5Share of holdings soldSold 13% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-059965, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 10, 2024 | SOpen-market sale COMMON STOCK | -658,809 | $1.22 | $802k | 4,429,449 | May 14, 2024 |
Related signals
Other insiders at IO Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | IOBTbuy IO Biotech, Inc. | Heidi Hunter director | $21k 15,000 shares | - | |
| 43Moderate | IO Biotech, Inc. | Qasim Iftikhar Ahmad Chief Medical Officer | $27k 31,350 shares | - | |
| 40Moderate | IO Biotech, Inc. | Devin Whittemore Smith General Counsel | $9,720 12,000 shares | +243% | |
| 40Moderate | IO Biotech, Inc. | Amy Sullivan Chief Financial Officer | $8,483 10,250 shares | +14% | |
| 46Moderate | IO Biotech, Inc. | Mai-Britt Zocca Chief Executive Officer | $10k 12,500 shares | +33% | |
| 22Weak | IOBTsell IO Biotech, Inc. | Novo Holdings A/S owner | $99k 75,000 shares | -2% | |
| 42Moderate | IOBTsell IO Biotech, Inc. | Novo Holdings A/S owner | $988k 658,809 shares | -11% | |
| 25Weak | IOBTbuy IO Biotech, Inc. | Brian Burkavage Chief Accounting Officer | $10k 10,000 shares | +667% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.